The market for age-related macular degeneration (AMD) drugs could grow at a compound annual growth rate of 8.9% and reach $11.5bn by 2026, according to a report.
Conducted by Global Data, the report covers the seven major AMD markets: the US, France, Germany, Italy, Spain, the UK and Japan.
Go deeper with GlobalData
The launch of new drugs and the increasing number of AMD cases in elderly people are predicted to be the driving factors for the anticipated growth of the market, which was worth an estimated $4.9bn in 2016.
Three new therapies are expected to be introduced to address geographic atrophy (GA), the late-stage dry age-related macular degeneration (dAMD), and three late-stage pipeline products for wet AMD (wAMD).
As dAMD currently lacks prescription medications, new drugs targeting this condition will play a major role in bolstering the market. These drugs include Apellis’ APL-2, Ophthotech’s Zimura and Allergan’s Brimo DDS.
APL-2 has already demonstrated positive profile in Phase IIa clinical trialS for GA and results from a Phase III trial are expected to get the drug blockbuster status by 2025.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataGlobal Data healthcare analyst Edit Kovalcsik believes that the losses incurred by Novartis over Eylea, an injection treatment for macular degeneration, will be counterbalanced with the launch of its brolucizumab drug, helping the company regain AMD market dominance.
“Once more efficacy and safety data accumulates and physicians become more accustomed to the use of brolucizumab, its advantage of less frequent dosing will allow it to claim an increasing share and become a first-line therapy if reimburse” Kovalcsik added.
Set to attain blockbuster status by 2021, brolucizumab is predicted to become the highest selling AMD drug by 2026, with global sales of $4.1bn.
